Tag:
Xgeva
Latest Headlines
Latest Headlines
Amgen's Xgeva wins NICE over with discount plan
The U.K.'s cost-effectiveness watchdogs have warmed up to Amgen's bone drug Xgeva. The company sweetened its discount offer, and that persuaded the National Institute for Health and Clinical Excellence to let Xgeva in.
NICE does an about-face, nixing cancer nod on Xgeva
The U.K.'s cost-effectiveness watchdog is having second thoughts about Amgen's new bone drug.
Amgen gets a no from the FDA on extended use of Xgeva
The FDA told Amgen no to an expanded use of its cancer treatment Xgeva, one of the company's most important drugs, saying the company could try again with more data.
FDA panel nixes new use for Amgen's Xgeva
The FDA's expert advisors didn't buy Amgen's ( $AMGN ) argument for earlier use of its bone drug Xgeva in prostate cancer patients. The idea: Treat advanced prostate cancer patients with...
Amgen's Xgeva faces FDA skepticism
The FDA isn't convinced that Amgen ( $AMGN ) needs another bone-metastasis indication for its new drug Xgeva . The drug is already approved to treat skeletal side effects in cancer patients, but Amgen
Amgen's Xgeva faces doubters on new indication
The FDA isn't convinced that Amgen ( $AMGN ) needs another bone-metastasis indication for its new drug Xgeva . The drug is already approved to treat skeletal side effects in cancer patients, but Amgen
Amgen's new meds beat estimates as anemia drugs slip
Amgen's ( $AMGN ) anemia drugs faltered again in the fourth quarter with sales declining 15% on Aranesp and 18% on Epogen . New bone drugs Xgeva and Prolia beat analyst estimates for their first full
Amgen aims for growth in bone drugs, overseas markets
Amgen's ( $AMGN ) incoming CEO has high hopes for this year. Now COO, Robert Bradway says he's looking for revenue growth in 2012, thanks in part to international expansion. Another driver: Sales of
Amgen's Prolia wins new uses, performs in study
It's a good news-good news day for Amgen ( $AMGN ). The company's new bone drug is gathering indications--and potential sales--like a snowball rolling downhill. Under the name Prolia, the drug won FDA
Breakthrough meds deliver the goods for BMS, Vertex
Fear not, pharma. There really might be hope ahead. Or such is the feeling among analysts chuffed by the early success of three new drugs. You know the ones: Bristol-Myers Squibb's melanoma drug
